ID   LN-229
AC   CVCL_0393
SY   LN 229; LN229; LNT-229
DR   BTO; BTO:0002004
DR   CLO; CLO_0007363
DR   EFO; EFO_0006637
DR   MCCL; MCC:0000288
DR   AddexBio; C0005017/4993
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2611
DR   BioGRID_ORCS_Cell_line; 929
DR   BioSample; SAMN03471191
DR   BioSample; SAMN03471692
DR   BioSample; SAMN10987619
DR   cancercelllines; CVCL_0393
DR   Cell_Model_Passport; SIDM00684
DR   ChEMBL-Cells; CHEMBL4295402
DR   ChEMBL-Targets; CHEMBL4296459
DR   CLS; 305043
DR   Cosmic; 849861
DR   Cosmic; 1746958
DR   Cosmic; 1995485
DR   Cosmic; 2302323
DR   Cosmic; 2367492
DR   Cosmic; 2491102
DR   Cosmic; 2516025
DR   Cosmic; 2580915
DR   Cosmic-CLP; 1240169
DR   DepMap; ACH-000595
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1240169
DR   GEO; GSM101615
DR   GEO; GSM101616
DR   GEO; GSM326200
DR   GEO; GSM397665
DR   GEO; GSM397666
DR   GEO; GSM481416
DR   GEO; GSM887270
DR   GEO; GSM888345
DR   GEO; GSM1374621
DR   GEO; GSM1670049
DR   GEO; GSM2113428
DR   GEO; GSM2113429
DR   GEO; GSM2113430
DR   GEO; GSM2113431
DR   IARC_TP53; 30212
DR   LiGeA; CCLE_871
DR   LINCS_LDP; LCL-1354
DR   Lonza; 1322
DR   PharmacoDB; LN229_841_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD003790
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0393
DR   PubChem_Cell_line; CVCL_0393
DR   Wikidata; Q54902771
RX   DOI=10.1007/0-306-46861-1_11;
RX   PubMed=7693337;
RX   PubMed=8509230;
RX   PubMed=9842975;
RX   PubMed=10416987;
RX   PubMed=14614447;
RX   PubMed=14655754;
RX   PubMed=16697959;
RX   PubMed=17595512;
RX   PubMed=19365568;
RX   PubMed=20504876;
RX   PubMed=21406405;
RX   PubMed=22460905;
RX   PubMed=22570425;
RX   PubMed=25485619;
RX   PubMed=25772239;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=25984343;
RX   PubMed=26496030;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=27412690;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=9842975); 31 hours (PubMed=25984343).
CC   HLA typing: A*03:01:01; B*35:01; C*04:01:01 (PubMed=27412690).
CC   HLA typing: A*03:01,03:01; B*35:01,35:01; C*04:01,04:01; DQA1*01:01,01:01; DQB1*05:01,05:01; DRB1*01:01,11:19 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975).
CC   Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (PubMed=10416987; Cosmic-CLP).
CC   Omics: Cell surface proteome.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=2.23%; East Asian, South=0%; South Asian=0.02%; European, North=59.47%; European, South=38.27% (PubMed=30894373).
CC   Misspelling: LN22; Cosmic=2580915.
CC   Derived from site: In situ; Brain, right frontal parieto-occipital cortex.
ST   Source(s): AddexBio; ATCC; Cosmic-CLP; PubMed=22570425; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10,11
ST   D16S539: 12
ST   D18S51: 13,15
ST   D21S11: 29,30
ST   D3S1358: 16,17
ST   D5S818: 11 (PubMed=25877200)
ST   D5S818: 11,12 (AddexBio; ATCC; Cosmic-CLP; PubMed=22570425)
ST   D7S820: 8,11 (AddexBio; ATCC; Cosmic-CLP; PubMed=22570425)
ST   D7S820: 11 (PubMed=25877200)
ST   D8S1179: 13,14
ST   FGA: 23
ST   Penta D: 10,11
ST   Penta E: 7,16
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,19
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 39
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=7693337;
RA   Li H., Hamou M.-F., de Tribolet N., Jaufeerally R., Hofmann M.,
RA   Diserens A.-C., Van Meir E.G.;
RT   "Variant CD44 adhesion molecules are expressed in human brain
RT   metastases but not in glioblastomas.";
RL   Cancer Res. 53:5345-5349(1993).
//
RX   PubMed=8509230; DOI=10.1002/ijc.2910540329;
RA   Rimoldi D., Romero P., Carrel S.;
RT   "The human melanoma antigen-encoding gene, MAGE-1, is expressed by
RT   other tumour cells of neuroectodermal origin such as glioblastomas and
RT   neuroblastomas.";
RL   Int. J. Cancer 54:527-528(1993).
//
RX   PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-z;
RA   Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N.,
RA   Krajewski S., Reed J.C., von Deimling A., Dichgans J.;
RT   "Predicting chemoresistance in human malignant glioma cells: the role
RT   of molecular genetic analyses.";
RL   Int. J. Cancer 79:640-644(1998).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=14614447; DOI=10.1038/sj.onc.1207198;
RA   Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.;
RT   "CP-31398, a novel p53-stabilizing agent, induces p53-dependent and
RT   p53-independent glioma cell death.";
RL   Oncogene 22:8233-8245(2003).
//
RX   PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x;
RA   Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.;
RT   "P-glycoprotein and multidrug resistance-associated protein mediate
RT   specific patterns of multidrug resistance in malignant glioma cell
RT   lines, but not in primary glioma cells.";
RL   Brain Pathol. 13:482-494(2003).
//
RX   PubMed=16697959; DOI=10.1016/j.ccr.2006.03.030;
RA   Lee J., Kotliarova S., Kotliarov Y., Li A.-G., Su Q., Donin N.M.,
RA   Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K.,
RA   Fine H.A.;
RT   "Tumor stem cells derived from glioblastomas cultured in bFGF and EGF
RT   more closely mirror the phenotype and genotype of primary tumors than
RT   do serum-cultured cell lines.";
RL   Cancer Cell 9:391-403(2006).
//
RX   PubMed=17595512; DOI=10.1159/000104150;
RA   Rieger J., Frank B., Weller M., Wick W.;
RT   "Mechanisms of resistance of human glioma cells to Apo2
RT   ligand/TNF-related apoptosis-inducing ligand.";
RL   Cell. Physiol. Biochem. 20:23-34(2007).
//
RX   PubMed=19365568; DOI=10.1371/journal.pone.0005209;
RA   Bax D.A., Little S.E., Gaspar N., Perryman L., Marshall L.,
RA   Viana-Pereira M., Jones T.A., Williams R.D., Grigoriadis A.,
RA   Vassal G., Workman P., Sheer D., Reis R.M., Pearson A.D.J., Hargrave D.,
RA   Jones C.;
RT   "Molecular and phenotypic characterisation of paediatric glioma cell
RT   lines as models for preclinical drug development.";
RL   PLoS ONE 4:E5209-E5209(2009).
//
RX   PubMed=20504876; DOI=10.1093/neuonc/noq051;
RA   Berger B., Capper D., Lemke D., Pfenning P.-N., Platten M., Weller M.,
RA   von Deimling A., Wick W., Weiler M.;
RT   "Defective p53 antiangiogenic signaling in glioblastoma.";
RL   Neuro-oncol. 12:894-907(2010).
//
RX   PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112;
RA   Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.-H.,
RA   Moncayo G., Hemmings B.A.;
RT   "MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta
RT   signaling pathway in human glioblastoma.";
RL   Cancer Res. 71:2392-2402(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25772239; DOI=10.1038/onc.2015.61;
RA   Vassallo I., Zinn P., Lai M., Rajakannu P., Hamou M.-F., Hegi M.E.;
RT   "WIF1 re-expression in glioblastoma inhibits migration through
RT   attenuation of non-canonical WNT signaling by downregulating the
RT   lncRNA MALAT1.";
RL   Oncogene 35:12-21(2016).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26496030; DOI=10.18632/oncotarget.6171;
RA   Patil V., Pal J., Somasundaram K.;
RT   "Elucidating the cancer-specific genetic alteration spectrum of
RT   glioblastoma derived cell lines from whole exome and RNA sequencing.";
RL   Oncotarget 6:43452-43471(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27412690; DOI=10.1074/mcp.M116.060350;
RA   Shraibman B., Kadosh D.M., Barnea E., Admon A.;
RT   "Human leukocyte antigen (HLA) peptides derived from tumor antigens
RT   induced by inhibition of DNA methylation for development of
RT   drug-facilitated immunotherapy.";
RL   Mol. Cell. Proteomics 15:3058-3070(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//